Dec 30, 2025 • Business Wire
BULLISH
Global Healthy Living Foundation and Guardant Health Announce Partnership to Advance Awareness of Early Colorectal Cancer Detection and Improve Access to Screening
The Global Healthy Living Foundation (GHLF) and Guardant Health have partnered to improve public understanding of colorectal cancer and encourage timely screening through patient-centered education. This collaboration aims to amplify patient and clinician voices, highlight accessible screening options, and ultimately empower more individuals to get screened early. The goal is to reduce disparities in cancer prevention and increase screening adherence by providing clear, trusted information.
Dec 29, 2025 • Yahoo Finance
NEUTRAL
Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Guardant Health, a prominent precision oncology company, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. Management is scheduled to present and hold a Q&A session on Monday, January 12, at 3:45 p.m. Pacific Time, with live and archived webcasts available on the company’s investor relations website. The company focuses on transforming patient care and accelerating cancer therapies through advanced blood and tissue tests, real-world data, and AI analytics.
Dec 29, 2025 • FinancialContent
BULLISH
Global Healthy Living Foundation and Guardant Health Announce Partnership to Advance Awareness of Early Colorectal Cancer Detection and Improve Access to Screening
The Global Healthy Living Foundation (GHLF) and Guardant Health have partnered to improve public understanding and encourage timely screening for colorectal cancer. This collaboration aims to raise awareness about the importance of early detection and accessible screening options, including less-invasive tests. Both organizations are committed to supporting public health, reducing disparities in cancer prevention, and empowering individuals with trusted information to maximize screening rates.
Dec 28, 2025 • MSN
BULLISH
Multiple analysts lift Guardant Health, Inc. (GH) targets on screening and data growth
Multiple analysts have raised their price targets for Guardant Health, Inc. (GH) due to accelerated screening growth and robust data coming out of their ECLIPSE trial. This positive outlook suggests increased confidence in the company's future performance following strong quarterly results.
Dec 28, 2025 • MarketBeat
SOMEWHAT-BULLISH
Capricorn Fund Managers Ltd Takes $2.26 Million Position in Guardant Health, Inc. $GH
Capricorn Fund Managers Ltd initiated a new position in Guardant Health, Inc. (NASDAQ:GH) in Q3, purchasing 36,200 shares valued at approximately $2.26 million. Despite significant insider selling over the past 90 days, institutional ownership remains high at 92.60%, and analysts generally rate the stock a "Moderate Buy" with an average price target of $96.71. Guardant Health reported strong Q3 earnings, beating analyst estimates, and saw a 38.5% year-over-year revenue increase.
Dec 26, 2025 • MarketBeat
SOMEWHAT-BULLISH
Guardant Health, Inc. (NASDAQ:GH) Given Average Recommendation of "Moderate Buy" by Brokerages
Guardant Health, Inc. (NASDAQ:GH) has received an average "Moderate Buy" rating from twenty-four brokerages, with an average 1-year price target of $96.71. Several analysts recently increased their price objectives for the stock, indicating strong confidence. Despite significant insider selling over the last quarter, institutional investors have been increasing their stakes in the company.